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OBJECTIVE—To investigate if recurrent autoimmunity ex-
plained hyperglycemia and C-peptide loss in three immuno-
suppressed simultaneous pancreas-kidney (SPK) transplant
recipients.
RESEARCH DESIGN AND METHODS—We monitored auto-
antibodies and autoreactive T-cells (using tetramers) and per-
formed biopsy. The function of autoreactive T-cells was studied
with in vitro and in vivo assays.
RESULTS—Autoantibodies were present pretransplant and per-
sisted on follow-up in one patient. They appeared years after
transplantation but before the development of hyperglycemia in
the remaining patients. Pancreas transplant biopsies were taken
within 1 year from hyperglycemia recurrence and revealed
-cell loss and insulitis. We studied autoreactive T-cells from the
time of biopsy and repeatedly demonstrated their presence on
further follow-up, together with autoantibodies. Treatment with
T-cell–directed therapies (thymoglobulin and daclizumab, all
patients), alone or with the addition of B-cell–directed therapy
(rituximab, two patients), nonspeciﬁcally depleted T-cells and
was associated with C-peptide secretion for 1 year. Autoreac-
tive T-cells with the same autoantigen speciﬁcity and conserved
T-cell receptor later reappeared with further C-peptide loss over
the next 2 years. Puriﬁed autoreactive CD4 T-cells from two
patients were cotransplanted with HLA-mismatched human islets
into immunodeﬁcient mice. Grafts showed -cell loss in mice
receiving autoreactive T-cells but not control T-cells.
CONCLUSIONS—We demonstrate the cardinal features of re-
current autoimmunity in three such patients, including the reap-
pearance of CD4 T-cells capable of mediating -cell destruction.
Markers of autoimmunity can help diagnose this underappreci-
ated cause of graft loss. Immune monitoring during therapy
showed that autoimmunity was not resolved by the immunosup-
pressive agents used. Diabetes 59:947–957, 2010
T
ype 1 diabetes is an autoimmune disease char-
acterized by the lymphocytic inﬁltration of the
pancreatic islets (insulitis), -cell destruction,
and loss of insulin secretion (1). Autoreactive
CD4 and CD8 T-cells and autoantibodies to islet cell
autoantigens are detected in patients and pre-diabetic
subjects, often preceding diabetes onset by months to
years. Insulin, GAD (GAD, 65-kDa isoform), the tyrosine-
like phosphatase protein IA-2, the islet-speciﬁc glucose-6-
phosphatase catalytic subunit-related protein (IGRP), and
the recently identiﬁed cation efﬂux transporter ZnT8 are
well characterized and commonly targeted autoantigens
(2–8).
Simultaneous pancreas-kidney (SPK) transplantation
from deceased donors restores insulin secretion in pa-
tients and corrects end-stage renal disease (9). Immuno-
logical failures occur in a minority of transplant recipients
and are usually categorized as chronic rejection. Another
possible cause of immunological failure is recurrence of
type 1 diabetes. This was initially reported a few weeks
after transplantation in recipients of the tail of the pan-
creas from living-related HLA-identical twins or siblings
who, because of HLA matching, received either no or
reduced immunosuppression (10–13). However, diabetes
recurrence was 10% in a large series of recipients of
deceased donor grafts given immunosuppression sufﬁcient
to prevent rejection (14). Further studies associated islet
cell autoantibodies with graft failure (15–19) but lacked
biopsy data, and rejection was not excluded. Two SPK
recipients had partial evidence for diabetes recurrence
(20), including limited biopsy data showing selective -cell
loss and/or insulitis and limited autoantibody data (20).
None of these studies assessed autoantigen-speciﬁc T-cells
in the context of graft loss. Islet autoimmunity is consid-
ered rare and is not routinely monitored in SPK recipients.
Thus, recurrence of type 1 diabetes in SPK recipients
remains incompletely characterized.
We investigated whether recurrent islet autoimmunity
explained the hyperglycemia and loss of insulin secretion
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the absence of rejection. The immunological assessment
included both retrospective and prospective testing for
autoantibodies and prospective testing for autoantigen-
speciﬁc T-cells. Monitoring was continued on extended
follow-up after patients were diagnosed with recurrence of
type 1 diabetes and received additional immunotherapy to
antagonize the autoimmune process. We also character-
ized the functional features of the autoreactive T-cells
detected in these patients in the context of recurring
diabetes, using both in vitro and in vivo experimental
assays to test the pathogenic effects of the autoreactive
T-cells.
RESEARCH DESIGN AND METHODS
The three SPK recipients studied (two males, one female) had type 1 diabetes
for many years and no C-peptide response to a Sustacal test before transplan-
tation. Pancreas transplants were bladder drained (exocrine) with systemic
venous efﬂuent, so that urine amylase reﬂects exocrine pancreas transplant
function. The patients were identiﬁed after the occurrence of hyperglycemia,
years after transplantation, in the absence of rejection and changes in
pancreas transplant exocrine function. All three recipients received immuno-
suppression with tacrolimus, mycophenolate mofetil, and steroids (for main-
tenance). They all reversed diabetes and normalized kidney function after SPK
transplantation. Patients signed informed consent to participate in research to
characterize their diabetes recurrence. The study was approved by the
University of Miami Institutional Review Board (protocol no. 20053039).
Analysis of pancreas transplant biopsies. Transplant biopsies were per-
formed based on clinical indication and with written informed consent.
Formalin-ﬁxed, parafﬁn-embedded sections were stained with hematoxylin
and eosin (H&E) and with speciﬁc antibodies to insulin, glucagon, CD3, CD4,
CD20, CD8, CD68, Fas, active caspase-3, human monocyte chemoattractant
protein-1 (MCP-1), chemokine (C-X-C motif) ligand 10 (CXCL10 or IP-10),
interferon- (IFN-), the proliferation marker Ki-67, and the enterovirus
protein VP-1 using immunohistochemistry and immunoﬂuorescence, as de-
tailed in the supplemental METHODS section in the online appendix, available at
http://diabetes.diabetesjournals.org/cgi/content/full/db09-0498/DC1.
Monitoring allograft function. C-peptide was assessed by radioimmunoas-
say (Diagnostic Products, Deerﬁeld, IL; intra- and interassay coefﬁcients of
variation 4.8 and 8.1%, respectively). The normal range is 0.8–4.0 ng/ml.
C-peptide levels are higher in SPK recipients because of the systemic venous
drainage of the transplanted pancreas. The exocrine function of the trans-
planted pancreas was monitored by measuring urine amylase levels. Kidney
allograft function was assessed by monitoring creatinine levels.
Autoantibody monitoring. Autoantibodies to GAD, IA-2, and ZnT8 were
measured using radioimmunoassays validated in the proﬁciency workshops of
the Immunology of Diabetes Society and Centers for Disease Control and
Prevention (21). Autoantibody levels are expressed as the ratio of the
autoantibody index levels of the patient over the cutoff index of each assay. A
ratio 1 denotes a positive result. Autoantibodies were measured retrospec-
tively in stored samples collected before the occurrence of diabetes symp-
toms, after which autoantibodies were measured prospectively.
In vitro T-cell studies. The prospective evaluation of circulating autoreac-
tive T-cells began after the onset of hyperglycemia. There were no frozen cells
for retrospective testing. We used tetramer-based assays to analyze autoreac-
tive T-cells with deﬁned autoantigen speciﬁcity (22,23). Tetramers are ﬂuo-
rescent-labeled, chimeric molecules consisting of four HLA-DR molecules
loaded with autoantigenic peptide. The HLA-DR speciﬁcity is matched to
patients’ HLA-DR type, and tetramer-peptide complexes bind to the T-cell
receptor (TCR) of autoreactive T-cells, allowing the enumeration of tetramer-
stained cells by ﬂow cytometry. Culture and antigen stimulation is required to
expand the antigen-responsive populations to detectable levels (0.1–2%),
given their extremely low frequency in the circulation (1:40,000–1:100,000).
The following peptides were used: 1) the modiﬁed GAD 555–567 peptide
(557i; NFIRMVISNPAAT); 2) the hemagglutinin (HA) 306–318 peptide
(PKYVKQNTLKLAT), a positive control peptide from the inﬂuenza hemagglu-
tinin; and 3) the OspA 161–175 peptide (VLKSYVLEGTLTAEK), derived from
the causative agent of Lyme disease. Responses to this antigen are uncom-
mon. After 12–14 days in culture, cells were stained with speciﬁc tetramers
and anti-CD4 and CD25 antibodies and analyzed by ﬂow cytometry. The
antigens were chosen based on the availability of HLA class II tetramers that
matched the HLA types of our patients and on the previously reported
association of T-cells reacting against these epitopes in patients with type 1
diabetes and pre-diabetic subjects (7,8,22,23). Patient 2 was tested for
IGRP-reactive CD8 T-cells using a class I HLA-A2 (A*0201) pentamer, since
she carried HLA class II genes for which there were no relevant tetramers.
Further methodological details are provided in supplemental METHODS section.
In vivo assessment of the pathogenicity of GAD-speciﬁc, autoreactive
CD4 T-cells. With approval of the Animal Care and Use Committee of the
University of Miami, islet transplantation was performed in athymic, immu-
nodeﬁcient mice (FoxN1 null; Harlan Laboratories), which do not reject
human islet grafts, using a previously reported procedure (24). After tetramer
staining, GAD-autoreactive CD4 T-cells were puriﬁed by ﬂuorescence-acti-
vated cell sorting, selecting the cells that were positive for CD4 and the
tetramer. Control T-cells were incubated with the HA or OspA peptides,
depending on HLA type and tetramer availability. The sorted cells were
directly cotransplanted with human islets under the kidney capsule using a
polyethylene catheter and precision syringe (Hamilton, Reno, NV). For mice
rendered diabetic with streptozotocin (200 mg/kg i.v.), post-transplantation
monitoring included assessment of nonfasting blood glucose levels. Nephrec-
tomy of the graft-bearing kidney was performed in animals achieving normo-
glycemia to observe a prompt return to hyperglycemia and exclude the effects
of residual function of the native pancreas. Mice were killed 1–2 weeks after
transplantation, and the grafts were examined for islet damage and -cell loss.
Formalin-ﬁxed parafﬁn-embedded sections of the grafts were stained with
H&E or with antibodies to insulin, glucagon, CD3, CD68, Fas, caspase 3,
MCP-1, IP-10, and IFN- by immunohistochemistry and immunoﬂuorescence
(see supplemental METHODS).
RESULTS
Recurrence of type 1 diabetes in SPK recipients, in
the absence of rejection. Figures 1–3 depict the clinical
history of the SPK recipients. All reversed diabetes after
transplantation. Insulin secretion became impaired and
hyperglycemia requiring insulin therapy ensued 5 (patient
1), 9 (patient 2), and 5 (patient 3) years after transplanta-
tion, respectively. They maintained normal exocrine pan-
creas graft function (secretion of urine amylase) and
normal kidney graft function throughout the follow-up,
even beyond the time of diabetes recurrence. Thus, the
patients had no clinical signs of rejection. They also lacked
donor-speciﬁc HLA antibodies at the time of diabetes
recurrence and on further follow-up (supplemental Tables
S3–S5). Patient 1 eventually developed donor-speciﬁc an-
tibodies about 5 years after diabetes recurrence, while
patient 3 developed donor-speciﬁc antibodies in connec-
tion with the rejection of his second pancreas transplant.
Thus, there was no clinical or laboratory evidence of
rejection in relation to the development of recurrent
diabetes. The selective loss of insulin secretion in the
absence of clinical signs of allorejection led to the suspi-
cion of recurrence of type 1 diabetes.
We performed retrospective autoantibody testing. In
patient 1, GAD and IA-2 autoantibodies were present
before transplantation (time 0), persisted despite immuno-
suppression, and titers increased on follow-up (Fig. 1A).
Patient 2 converted to GAD and IA-2 autoantibody
positivity 6 years after transplantation (Fig. 2A). ZnT8
autoantibodies were never detected in patients 1 and 2
(not shown). Patient 3 had been autoantibody-negative
before transplant and for almost 5 more years and
converted to GAD and ZnT8 autoantibody positivity 3
months before the recurrence of hyperglycemia (Fig.
3A). At that time, there was a sharp rise in ZnT8
autoantibodies, closely followed by a similar rise of
GAD autoantibodies. Insulin autoantibodies were also
detected during that period, before reinstitution of
insulin therapy (not shown).
All patients underwent a pancreas transplant biopsy
within a year from the recurrence of hyperglycemia. There
was no evidence of rejection in either pancreas or kidney
transplants. However, there was -cell loss and insulitis,
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and 2B) had peri-insulitis to severe insulitis affecting many
islets with inﬁltrating T-cells (CD3, CD4, CD8) and B-cells
(CD20) detected by immunostaining. Many islets no longer
stained for insulin and many more appeared damaged with
reduced insulin content. Yet several islets appeared
healthy with normal proportions of -cells. In contrast,
patient 3 had minimal insulitis, but there was dramatic loss
of -cells (Fig. 3A, inset), suggesting that the insulitis
process had mostly run its course. In all patients, inﬁl-
trates consisted mostly of CD8 T-cells, whereas CD4
T-cells appeared much less frequent. B-cells were less
represented than T-cells. Additional biopsy data are re-
ported in the supplemental data, and Figs. S5–S17, S18–
S27, and S28–S35 for patients 1–3, respectively. As we
previously reported (25), biopsies of these patients dem-
onstrated ductal cells expressing insulin (supplemental
Figs. S17, S27, and S34), rarely expressing the proliferation
marker Ki-67 (Fig. S35), suggesting a potential mechanism
of pancreas remodeling and perhaps -cell regeneration.
Ki-67 expression was not observed in residual -cells
within the islets (not shown) in the biopsy material
available. We detected VP-1 protein in the islets of patient
2 (Fig. S26), which was colocalized with insulin by confo-
cal microscopy and indicated -cell infection with Cox-
sackie B virus, which has been associated with type 1
diabetes (26,27). We did not detect VP-1 expression in the
islets of the other two patients and in biopsies from three
additional SPK recipients who were normoglycemic and
autoantibody negative; two other normoglycemic and au-
toantibody-negative SPK recipients expressed VP-1 in ei-
ther -cells or -cells (not shown).
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FIG. 1. Clinical course, autoimmunity assessment, and biopsy in patient 1. Patient 1 was a 41-year-old Caucasian male [HLA A2/A3, B57/B60, DR4
(DRB1*0405)/DR6] who developed type 1 diabetes at age 7 years. He received an SPK transplant from an HLA A2/A30, B41/B60, DR4/DRX donor
at age 32 years. The transplant reversed diabetes, but the patient returned to insulin dependence 5 years later, while kidney and exocrine
pancreas allografts had normal function. A: Autoantibody levels before transplant and on follow-up. The patient had GAD and IA-2 autoantibodies
before transplantation, which persisted despite immunosuppression, and titers increased on follow-up. Color-matched, horizontal lines represent
the cutoff level for each autoantibody. For all autoantibodies, a value >1 denotes a positive result. B: Pancreas transplant biopsy stained as
labeled, obtained 6 months after the recurrence of hyperglycemia. Insulitis and -cell loss are shown. C: Serum C-peptide levels and % of GAD
tetramer–positive T-cells in the CD4 T-cell population from the time of hyperglycemia recurrence. C-peptide was still detectable at diagnosis,
conﬁrming the function of residual -cells observed at biopsy. Autoreactive T-cells were detected at the time of biopsy, 6 months after
the recurrence of hyperglycemia on two samples, and again at several time points 1 year after treatment. The horizontal blue line
represents the cutoff of the tetramer assay (0.25%). D: Flow cytometry plots demonstrating GAD-autoreactive CD4 T-cells. The numbers
above the plots identify the same sample in C. Tetramer staining with irrelevant peptide was <0.1% (not shown). DM, diabetes; Tx,
treatment. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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time of biopsy for all patients. In patients 1 and 3,
GAD-autoreactive CD4 T-cells were detected from periph-
eral blood samples using HLA class II tetramer-based
assays: these were restricted by HLA-DR4 (DRB1*0405)
(patient 1, Fig. 1C and D) and by HLA-DRB4*0101 (patient
3, Fig. 3B and C, who also had DRB1*0402-restricted
GAD-autoreactive CD4 T-cells, not shown). Autoreactive
T-cells were detected on multiple occasions in both pa-
tients. In patient 2, we detected IGRP-speciﬁc autoreactive
CD8 T-cells using an HLA-A2 (A*0201) class I pentamer
from a blood sample obtained at the time of biopsy (Fig.
2C and D).
Autoreactive T-cells are temporarily and nonspeciﬁ-
cally inhibited by T-cell– and B-cell–directed immu-
nosuppression, and their reappearance is followed by
further loss of insulin secretion. In patient 1, detectable
C-peptide levels (Fig. 1C) conﬁrmed the function of the
residual -cells identiﬁed at biopsy (Fig. 1B). To salvage
the residual -cells, the patient received daclizumab (1
mg/kg, 2, 2 weeks apart) and thymoglobulin (1 mg  kg
1 
day
1, 5 days). After treatment, GAD-autoreactive CD4
T-cells became undetectable (Fig. 1C), similar to T-cells
responding to a control antigen (not shown), consistent
with nonspeciﬁc immunosuppression. Autoantibody levels
ﬂuctuated but persisted on follow-up (Fig. 1A). While the
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FIG. 2. Clinical course, autoimmunity assessment, and biopsy in patient 2. Patient 2 is a Caucasian female (HLA A2/A24, B44/B56, DR5/DR9) who
developed type 1 diabetes at age 8 years. She received an SPK transplant from an HLA A2/A3, B7/B14, DR7/DR9 donor at age 30 years. Her
pancreas transplant successfully reversed diabetes. After approximately 9 years, the patient developed hyperglycemia requiring insulin therapy,
while the function of the kidney and exocrine pancreas allografts remained unchanged. A: Autoantibody levels before transplant and on follow-up.
The patient converted to GAD and IA-2 autoantibody positivity 6 years after transplantation. Hyperglycemia ensued 3.5 years after autoantibody
conversion. B: Pancreas transplant biopsy stained as labeled, obtained 7 months after the recurrence of hyperglycemia. There was evidence for
insulitis and -cell loss. C: C-peptide levels from the time of hyperglycemia recurrence and % of IGRP tetramer–positive T-cells in the CD8 T-cell
population. The horizontal blue line represents the cutoff of the T-cell assay (0.1%). Percentage of cells plotted is the speciﬁc staining value
shown in D minus the background staining with control peptide. Circulating CD8 T-cells reacting against IGRP were found in a sample obtained
at the time of biopsy and again 1 year after treatment. D: Flow cytometry plots showing IGRP-speciﬁc autoreactive CD8 T-cells. Staining with
tetramers loaded with a control peptide yielded 0.1% background staining levels, gating on PBMC (not shown). The numbers above the plots
identify the IGRP T-cell measurements in C, thus corresponding to the samples measured closest to the onset of hyperglycemia and over 1 year
after treatment. DM, diabetes; Tx, treatment. (A high-quality digital representation of this ﬁgure is available in the online issue.)
TYPE 1 DIABETES RECURRENCE IN SPK PATIENTS
950 DIABETES, VOL. 59, APRIL 2010 diabetes.diabetesjournals.orgpatient remained insulin-dependent throughout, C-peptide
levels increased and remained detectable for 1 year after
treatment. C-peptide secretion declined over the subse-
quent 2 years, following the return of circulating GAD-
autoreactive CD4 T-cells (Fig. 1C and D), and were
undetectable 3 years after treatment (Fig. 1C).
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FIG. 3. Clinical course, autoimmunity assessment, and biopsy in patient 3. Patient 3 is a 38-year-old Caucasian male [HLA A26/A30, B38/B58,
DR3/DR4 (DRB1*0402)] who developed type 1 diabetes at age 12 years. He received an SPK transplant from an HLA-A23/A33, B7/B52, DR2/DR10
donor at age 27 years. The pancreas transplant successfully reversed diabetes. Five years later, the patient developed hyperglycemia requiring
insulin therapy with unchanged function of the kidney and exocrine pancreas allografts. A: Autoantibody levels before transplant and on
follow-up. Color-matched blue and black horizontal lines represent cutoffs for GAD/IA-2 and ZnT8 autoantibodies, respectively. The patient had
been autoantibody negative before transplant and for almost 5 years on follow-up, but converted to GAD and ZnT8 autoantibody positivity about
3 months before the recurrence of hyperglycemia. At the time, there was a sharp rise in ZnT8 autoantibodies, shortly thereafter followed by a
similar rise in GAD autoantibody levels, peaking at levels that were 40-fold and 10-fold higher than the upper limit of normal, respectively. Inset:
Hormone stains in the ﬁrst pancreas transplant biopsy obtained at retransplantation demonstrate -cell loss. B: Serum C-peptide levels and %
of GAD tetramer–positive T-cells in the CD4 T-cell population from the time of hyperglycemia recurrence. Patient 3 had no residual C-peptide
secretion in the fasting state and no response to a Sustacal meal test (not shown) at the onset of hyperglycemia. C-peptide secretion was restored
by retransplantation but was lost again after rejection of the second pancreas transplant. GAD-speciﬁc autoreactive CD4 T-cells were ﬁrst
studied in the sample obtained before the immunosuppression required for the second transplant. Autoreactive T-cells became undetectable after
immunosuppression, but eventually rebounded and were detected on multiple occasions. The horizontal blue line represents the cutoff of the
tetramer assay (0.25%). C: Flow cytometry plots demonstrating strong responses of GAD autoreactive, CD4 T-cells. Numbers above the plots
correspond to those in B. Tetramer staining with irrelevant peptide was <0.1% (not shown). D: Biopsy of the second pancreas graft showing
rejection. CD4 inﬁltrates are seen near residual insulin-stained areas. DM, diabetes; Tx, treatment. (A high-quality digital representation of this
ﬁgure is available in the online issue.)
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residual -cells at biopsy (Fig. 2B). The patient received
daclizumab (1 mg/kg, 2, 2 weeks apart), thymoglobulin
(1 mg  kg
1  day
1, 5 days), and rituximab (375 mg/m
2,
1) after the ﬁrst thymoglobulin dose. After treatment,
HLA-A2–restricted IGRP-autoreactive CD8-T-cells were
not detected on two separate occasions (Fig. 2C), while
the patient was T-cell depleted. T-cell counts normalized 6
months after therapy and IGRP-autoreactive CD8 T-cells
reappeared 1 year after treatment (Fig. 2C and D). Auto-
antibody levels fell after therapy but rebounded after the
reappearance of IGRP-autoreactive CD8 T-cells (Fig. 2A).
C-peptide persisted after therapy but declined after the
reappearance of IGRP-autoreactive CD8 T-cells (Fig. 2C
and D) and the subsequent elevation of autoantibody
levels (Fig. 2A). The patient remained insulin dependent
thereafter.
Patient 3 had no residual insulin secretion and received
a second pancreas transplant from an HLA-A1/A29, B8/
B44, DR2/DR3 donor. The ﬁrst pancreas transplant was
biopsied at retransplantation and demonstrated severe
-cell loss in the absence of pancreas rejection (Fig. 3A,
inset). The immunosuppression for the second transplant
consisted of daclizumab (1 mg/kg, 2, 2 weeks apart),
thymoglobulin (1 mg  kg
1  day
1, 5 days), rituximab
(375 mg/m
2, 1), and plasmapheresis (pretransplant and
every other day, 3). Maintenance doses of tacrolimus,
mycophenolate mofetil, and steroids were continued. GAD
and ZnT8 autoantibodies were declining before retrans-
plantation and continued to decline afterward (Fig. 3A).
Serial measurements performed during a plasmapheresis
course initiated at the time of the second pancreas trans-
plant showed no effect on GAD autoantibodies, while ZnT8
autoantibody levels declined (supplemental Fig. S1). After
the immunosuppression, GAD-autoreactive CD4 T-cells
became undetectable (Fig. 3B and C). The second pan-
creas transplant restored insulin secretion (Fig. 3B) and
the patient became normoglycemic. Fifteen months later,
there was a mild rejection episode, documented by percu-
taneous biopsy, which resolved with steroids. The patient
became hyperglycemic 1.5 years later. At biopsy, the
second pancreas transplant appeared as a 1.5-cm calciﬁed
ﬁbrotic remnant with evidence of both acute and chronic
rejection (Fig. 3D), and donor-speciﬁc antibodies against
the second donor were demonstrated (supplemental Table
S5). Rejection was associated with reactivation of autoim-
munity, as it was preceded by another steep elevation of
GAD autoantibodies and to a lesser extent of ZnT8 auto-
antibodies (Fig. 3A). GAD-autoreactive CD4 T-cells reap-
peared as well and continued to be detected in multiple
peripheral blood samples (Fig. 3B and C) and in peri-
pancreatic lymph nodes (not shown) from the ﬁrst pancreas
transplant obtained at the time of the second pancreas
transplant biopsy. The patient eventually lost stimulated
C-peptide secretion 3 years after re-transplantation (Fig. 3B)
and became insulin dependent.
In vitro functional assessment of autoreactive T-
cells. We studied GAD-speciﬁc CD4 T-cell clones from
patients 1 and 3 (supplemental data and Fig. S2 and S3).
For both patients, clones derived from before and after
treatment samples displayed Th1 bias with predominant
IFN- secretion (supplemental Tables S1 and S2). For
patient 1, all clones expressed the V  5.1 TCR chain,
although the CDR3 sequence between pre- and post-
treatment samples was not identical (Table S1). For pa-
tient 3, TCR analysis of several DRB1*0401-restricted
clones from before and after treatment showed the same
TCR V  9 chain and identical CDR3 sequence (Table
S2). For patient 2, we tested the speciﬁcity and cyto-
toxic effects of the IGRP-autoreactive CD8 T-cells ob-
tained from the sample closest to the recurrence of
hyperglycemia (sample no. 1, Fig. 2C and D) and found
that they speciﬁcally targeted peptide-loaded cell lines
(Fig. S4). Thus, the IGRP-autoreactive CD8 T-cells from
patient 2 were functional and mediated antigen-speciﬁc
cytotoxicity.
Assessing the pathogenicity of GAD-autoreactive
CD4 T-cells using an in vivo transplant model. We
cotransplanted human islets from unrelated donors under
the kidney capsule of immunodeﬁcient mice together with
patient-derived, tetramer-positive, ﬂuorescence-activated
cell sorting–puriﬁed, GAD-speciﬁc CD4 T-cells. In the ﬁrst
experiment, we studied a sample (no. 10, Fig. 1C and D)
from patient 1, which yielded a very strong CD4 T-cell
response to GAD. The grafts were examined after 1 week.
We observed damaged islets and -cell loss only in the
mouse that received the GAD-speciﬁc CD4 T-cells (Fig.
4A) but not in the mice that received islet and control
T-cells directed against the HA antigen (Fig. 4B) or islets
alone (Fig. 4C). To assess speciﬁcity, we counted - and
-cells in sections from the whole grafts. We observed
/-cell ratios of 1.0 (islets alone; 1,025 -cells and 951
-cells counted), 1.7 (islet 	 control T-cells; 582 -cells
and 342 -cells), and 0.6 (islets 	 GAD-autoreactive CD4
T-cells, 278 -cells and 446 -cells). While the ratios
observed for the control grafts are close to that reported in
human islets (28,29), the ratio observed in the graft with
autoreactive T-cells suggests preferential -cell loss. We
could not identify expression of MCP-1, IP-10, IFN-, Fas,
and caspase-3 in the transplanted islet grafts (not shown).
In the second experiment, autoreactive T-cells from
patient 3 were cotransplanted with islets in immunodeﬁ-
cient mice that had been previously rendered diabetic with
streptozotocin. Grafts were retrieved after 2 weeks.
Once again, we observed severe islet damage and -cell
loss only in the graft receiving the GAD-reactive CD4
T-cells (Fig. 5A) and not in the control mice (Fig. 5B and
C) receiving islets alone or islets together with activated
CD4 T-cells that did not respond to the OspA control
peptide, in essence representing a polyclonal population.
We observed /-cell ratios of 1.3 (islet alone, 415 -cells
and 318 -cells), 2.0 (islet 	 control T-cells, 294 -cells and
145 -cells), and 0.7 (islet 	 GAD-autoreactive CD4 T-
cells, 43 -cells and 61 -cells), again suggesting preferen-
tial -cell loss. Expression of MCP-1, IP-10, IFN-, and Fas
was not observed in the retrieved islet grafts (not shown).
However, we identiﬁed rare -cells expressing the active
form of caspase-3, indicating apoptosis, in the graft that
received GAD T-cells from patient 3 (Fig. S37). Caspase-
3–expressing -cells were not observed in the control
grafts (not shown). Both control mice reversed their
diabetes after islet transplantation, while the mouse that
received the GAD autoreactive CD4 T-cells remained
hyperglycemic for the entire duration of the experiment
(Fig. 5D).
In both experiments, there was no evidence of human
lymphocytes or antigen-presenting cells persisting in the
graft after 1–2 weeks by CD3 and CD68 staining (not
shown), respectively. We also analyzed spleen, pancreas,
lymph nodes (pancreatic and inguinal), and blood from the
transplanted mice for the presence of human T-cells.
These were undetectable by ﬂow cytometry analysis and
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Because a very small number of T-cells were transplanted,
surviving cells could have been diluted below current
detection limits. After prolonged culture and in vitro
activation, transplanted lymphocytes were likely to die in
the absence of further stimuli and growth factors.
DISCUSSION
Our ﬁndings demonstrate the cardinal features of disease
recurrence in immunosuppressed SPK recipients, in the
absence of rejection, either clinically or on biopsy: 1)
hyperglycemia without functional impairment of the exo-
crine pancreas or kidney allografts, associated with selec-
tive loss of insulin secretion; 2) insulitis and/or -cell loss
at biopsy; 3) persistence or reappearance of autoantibod-
ies preceding diabetes recurrence; and 4) presence of
circulating autoreactive CD4 or CD8 T-cells, assessed with
autoantigen-speciﬁc tetramer assays, around the time of
diabetes recurrence and on further follow-up. Speciﬁcally,
we demonstrated GAD-autoreactive CD4 T-cells in the
circulation of patients 1 and 3. Of note, patient 3 also
harbored such cells in the local lymph node of the ﬁrst
pancreas transplant, which further suggests involvement
in the autoimmune process. Patient 2 had IGRP-autoreac-
tive CD8 T-cells. Thus, markers of islet autoimmunity as
used in our study can help in diagnosing disease recur-
rence. Although measures of T-cell reactivity derived from
stimulated in vitro responses are semiquantitative and
response levels ﬂuctuate, there often were consistent
responses at multiple time points that reﬂected autoimmu-
nity and the impact of immunotherapy. Thus, tetramer-
based assays can be informative in the context of
intervention studies. Unpublished data from ongoing stud-
ies in our cohort of SPK recipients suggest that autoanti-
body conversion increases the risk of developing recurrent
type 1 diabetes (odds ratio 15.33, P  0.000002, comparing
to autoantibody negative in an analysis of 200 SPK recip-
ients); preliminary studies suggest that autoreactive T-
cells tend to be roughly twice as frequent in SPK recipients
with recurrent type 1 diabetes compared with normogly-
cemic recipients, noting that most normoglycemic recipi-
ents with autoreactive T-cells were also autoantibody
positive. Further studies will help determine whether
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based prediction.
Autoantibodies preceded hyperglycemia by several
years in patients 1 and 2, suggesting that the recurrent
autoimmunity in immunosuppressed patients may
progress slower than in nonimmunosuppressed recipi-
ents of HLA-matched living-related donors, who devel-
oped disease recurrence within weeks of transplant
(11,12,14,30). A slower course was also reported in the
two other immunosuppressed patients with disease re-
currence reported in the literature (20). However, pa-
tient 3 developed hyperglycemia within a few months
from the autoantibody conversion, which involved the
almost simultaneous appearance of very high titers of
ZnT8 and GAD autoantibodies. Overall, autoantibodies
were good markers of autoimmunity, showing conversions
or level ﬂuctuations that reﬂected clinical course and
response to treatment.
Using HLA class I pentamers and class II tetramers,
respectively, we puriﬁed IGRP-speciﬁc CD8 T-cells and
GAD-speciﬁc autoreactive CD4 T-cells for phenotypic and
functional studies. The IGRP-speciﬁc autoreactive CD8
T-cells identiﬁed in patient 2 recognize the same epitope
described in patients with new-onset type 1 diabetes and
at-risk subjects (7,8). These cells had antigen-speciﬁc
cytotoxic effects, which further implicate an IGRP-respon-
sive CD8 T-cell population in disease recurrence. Associ-
ations of type 1 diabetes recurrence with autoreactive CD8
T-cells (31,32) and autoantibodies (33) are also emerging
in islet transplant recipients. A role for memory pheno-
types is suggested in both spontaneous disease (34,35) and
its recurrence in islet transplant recipients (36). Our
preliminary analysis of TCR clonotypes in patients 1 and 3
(37) and the additional data presented here (Tables S1 and
S2) reveal that GAD-autoreactive CD4 T-cells expressing
identical or similar V  chains (5.1 and 9) and CDR3
sequences reappeared after immunosuppression in pa-
tients 1 and 3. The usage of V  5.1 is common by
GAD-autoreactive, HLA-DRB1*04-restricted CD4 T-cells in
patients who respond to the same GAD 555–567 peptide
(22,23). The persistence of autoreactive T-cells against the
same autoantigen, expressing the same or closely related
TCR V  chains, is consistent with a memory response
associated with recurrent autoimmunity in our SPK recip-
ients. The activation and memory status could not be
assessed ex vivo, since these autoreactive T-cells were
identiﬁed after in vitro culture and stimulation.
We took advantage of the simultaneous availability of
sizable populations of highly puriﬁed, GAD-autoreactive
CD4 T-cells from our patients and of human islets from
unrelated donors to test the pathogenic effects of the
autoreactive lymphocytes in vivo using a cotransplanta-
tion model into immunodeﬁcient mice. In the ﬁrst exper-
iment, we transplanted highly puriﬁed CD4 T-cells with
single autoantigen speciﬁcity, reacting against GAD or the
HA control antigen derived from patient 1. We observed
preferential -cell loss in the mice receiving the GAD-
speciﬁc T-cells, but not in the mice receiving HA-speciﬁc,
control T-cells. We had a similar outcome in the second
experiment, in which the control T-cells were a polyclonal
population that had not responded to the OspA antigen, as
expected in most subjects. Of note, some loss of -cells is
reported in mouse models during the development of
autoimmune diabetes (38) and the GAD autoantigen is also
expressed by -cells in human islets (39). Importantly, the
pathology observed is consistent with the metabolic fol-
low-up data of the transplanted mice. We interpret these
ﬁndings as collectively showing that GAD-speciﬁc CD4
T-cells from patients 1 and 3 directly mediated signiﬁcant
-cell damage in our in vivo transplantation model.
Because of their extemporaneous nature, these experi-
ments offer limited information about the mechanisms
involved in the observed -cell destruction, but some
speculations are possible. The transplanted CD4 T-cells
were already activated in vitro, as shown by CD25 expres-
sion. In addition, human CD4 T-cells can present antigen
to each other through their HLA class II molecules, which
could help with maintaining an activated status (40).
Whereas we did not have fresh antigen-presenting cells
from these patients at the time of the experiments, we
cannot exclude that residual antigen-presenting cells con-
tained in the puriﬁed T-cell inoculum could have contrib-
uted to T-cell activation. Moreover, antigen-presenting
cells resident in the islets could have presented GAD
peptides but not HA antigen, which could help explain
why only the GAD-autoreactive T-cells mediated signiﬁ-
cant damage. Presentation could occur despite HLA
mismatch, similar to the direct presentation pathway
described in transplantation (41,42). Accordingly, the Gill
group reported that MHC-mismatched islet allografts are
vulnerable to autoimmune destruction by autoreactive
CD4 T-cells, using a mouse model but not testing human
cells (41). In these experiments, we transplanted primary
autoreactive CD4 T-cells immediately after puriﬁcation.
Thus, we could not assess their speciﬁc cytokine proﬁles.
However, the autoreactive CD4 T-cell clones reported here
for patients 1 and 3 predominantly produced IFN- and
TNF- upon antigen-speciﬁc stimulation. Increased -cell
sensitivity to cytokines compared with other islet cell
types may partially explain the preferential -cell loss
observed (43). The ﬁnding that signiﬁcant and preferential
-cell destruction was seen only in the mice transplanted
with the GAD-speciﬁc T-cells is further evidence that
-cell destruction was mediated by an autoimmune rather
than allogeneic response and did not result from nonspe-
ciﬁc inﬂammation caused by T-cells responding to a
control antigen. Although limited, these data offer an
experimental assessment of human autoreactive T-cells
that is rarely feasible in clinical studies. By using a model
that recapitulates the transplant setting, the data support
the concept that autoreactive T-cells played a role in the
recurrent autoimmunity observed in our patients.
We treated recurrent autoimmunity to salvage residual
-cells in patients 1 and 2. The third patient had no
residual C-peptide and was re-transplanted. As patients
were diagnosed at different times, we used a stepwise
approach based on the experience from each patient and
tested progressively more sophisticated immunosuppres-
sive therapies to target T-cells, B-cells, and autoantibodies
(thymoglobulin, daclizumab, rituximab, and plasmaphere-
sis). C-peptide secretion was maintained for up to 3 years
in patient 1 and patient 2, although both remained insulin-
dependent throughout the follow-up. Treatment depleted
T-cells nonspeciﬁcally, including the autoreactive ones.
However, autoreactive T-cells reappeared 1 year after
treatment. Their reappearance was followed by a progres-
sive decline in C-peptide levels. Both patient 1 and 2 had
rising autoantibodies mirroring the reappearance of auto-
reactive T-cells. At the time of re-transplantation, patient 3
received immunosuppression and plasmapheresis. Al-
though GAD and ZnT8 autoantibody levels were declining
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not affect GAD autoantibodies but lowered ZnT8 autoan-
tibodies. This ﬁnding is consistent with earlier studies
showing that plasmapheresis lowers islet cell antibodies
other than GAD autoantibodies in patients with newly
diagnosed type 1 diabetes (44). Thus, ZnT8 autoantibodies
may be responsive to plasmapheresis. Patient 3 eventually
rejected the second transplant, but also experienced reac-
tivation of islet autoimmunity marked by the re-expression
of ZnT8 and GAD autoantibodies and the return of circu-
lating GAD-autoreactive CD4 T-cells with the same TCR
clonotype observed when disease recurred in the ﬁrst
pancreas transplant. The treatment with T-cell– and B-
cell–directed immunosuppression affected autoimmunity
temporarily and nonspeciﬁcally.
While limited to three patients, our clinical experience is
consistent with results from clinical trials in recent-onset
type 1 diabetes, as temporary persistence of C-peptide
secretion is followed by eventual decline after treatment
with immunosuppressive agents (45–47). Our study pro-
vides an assessment of autoreactive T-cells and autoanti-
bodies in relation to immunosuppressive therapy for islet
autoimmunity, noting that rituximab and thymoglobulin
are currently being tested in clinical trials of new-onset
patients (48) (www.diabetestrialnet.org). Our intensive
monitoring suggests that nonspeciﬁc immunosuppression
may not achieve long-lasting inhibition of islet autoimmu-
nity. Future combinatorial regimens could attempt to
tolerize newly emerging T-cells and memory cells during
post-depletion recovery (49,50).
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